Show simple item record

dc.contributor.authorCrabb, SJ
dc.contributor.authorBirtle, AJ
dc.contributor.authorMartin, K
dc.contributor.authorDowns, N
dc.contributor.authorRatcliffe, I
dc.contributor.authorMaishman, T
dc.contributor.authorEllis, M
dc.contributor.authorGriffiths, G
dc.contributor.authorThompson, S
dc.contributor.authorKsiazek, L
dc.contributor.authorKhoo, V
dc.contributor.authorJones, RJ
dc.date.accessioned2020-12-21T03:08:48Z
dc.date.available2020-12-21T03:08:48Z
dc.date.issued2017-10-01
dc.identifierpii: 10.1007/s10637-017-0433-4
dc.identifier.citationCrabb, S. J., Birtle, A. J., Martin, K., Downs, N., Ratcliffe, I., Maishman, T., Ellis, M., Griffiths, G., Thompson, S., Ksiazek, L., Khoo, V. & Jones, R. J. (2017). ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer. INVESTIGATIONAL NEW DRUGS, 35 (5), pp.599-607. https://doi.org/10.1007/s10637-017-0433-4.
dc.identifier.issn0167-6997
dc.identifier.urihttp://hdl.handle.net/11343/257091
dc.description.abstractBackground Docetaxel and prednisolone chemotherapy (DP) extends survival in metastatic castration resistant prostate cancer (mCRPC). However, emergent clinical resistance is almost inevitable. AKT pathway activation is highly prevalent in mCRPC contributing to disease progression and DP resistance. AZD5363 is a potent oral pan-AKT inhibitor with pre-clinical data indicating activity in mCRPC and synergy with docetaxel. Methods This phase I trial was to determine an AZD5363 recommended phase II dose (RP2D) for combination with DP. Eligibility criteria included chemotherapy naive mCRPC, PSA or radiographic disease progression and ECOG performance status 0 or 1. Treatment comprised DP (75 mg/m2, IV, day 1 and 5 mg BID, PO, day 1-21 respectively for ten cycles) and AZD5363 to disease progression for all patients. We utilised a 3 + 3 dose escalation design to determine a maximum tolerated dose according to defined dose limiting toxicity criteria assessed using CTCAE version 4.03. Planned AZD5363 dose levels were 320 mg (DL1), 400 mg (DL2) and 480 mg (DL3), BID, PO, 4 days on/3 days off, from day 2 of each cycle. Results 10 patients were treated. Dose limiting toxicities affected 2 patients (grade 3 rash ≥5 days; grade 3 diarrhoea) in DL2. The commonest grade 3 or 4, AZD5363 related, symptomatic adverse events were rash and diarrhoea. Hyperglycaemia affected all patients but was self-limiting. PSA reduction to <50% at 12 weeks occurred in 7 patients. Conclusions The RP2D for AZD5363 is 320 mg BID, 4 days on/3 days off, in combination with full dose DP for mCRPC.
dc.languageEnglish
dc.publisherSPRINGER
dc.titleProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer
dc.typeJournal Article
dc.identifier.doi10.1007/s10637-017-0433-4
melbourne.affiliation.departmentMedicine and Radiology
melbourne.source.titleInvestigational New Drugs
melbourne.source.volume35
melbourne.source.issue5
melbourne.source.pages599-607
dc.rights.licenseCC BY
melbourne.elementsid1242757
melbourne.contributor.authorKhoo, Vincent
dc.identifier.eissn1573-0646
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record